Cargando…
Elevated expression of CDK4 in lung cancer
BACKGROUND: The aim of the present study was to analyze the expression of Cyclin-dependent kinase 4 (CDK4) in lung cancer and its correlation with clinicopathologic features. Furthermore, the involvement of CDK4-mediated cell cycle progression and its molecular basis were investigated in the pathoge...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3094221/ https://www.ncbi.nlm.nih.gov/pubmed/21477379 http://dx.doi.org/10.1186/1479-5876-9-38 |
_version_ | 1782203519949864960 |
---|---|
author | Wu, Aibing Wu, Bin Guo, Jinsong Luo, Weiren Wu, Dong Yang, Huiling Zhen, Yan Yu, Xiaoli Wang, Hao Zhou, Ying Liu, Zhen Fang, Weiyi Yang, Zhixiong |
author_facet | Wu, Aibing Wu, Bin Guo, Jinsong Luo, Weiren Wu, Dong Yang, Huiling Zhen, Yan Yu, Xiaoli Wang, Hao Zhou, Ying Liu, Zhen Fang, Weiyi Yang, Zhixiong |
author_sort | Wu, Aibing |
collection | PubMed |
description | BACKGROUND: The aim of the present study was to analyze the expression of Cyclin-dependent kinase 4 (CDK4) in lung cancer and its correlation with clinicopathologic features. Furthermore, the involvement of CDK4-mediated cell cycle progression and its molecular basis were investigated in the pathogenesis of lung cancer. METHODS: Using immunohistochemistry analysis, we analyzed CDK4 protein expression in 89 clinicopathologically characterized lung cancer patients (59 males and 30 females) with ages ranging from 36 to 78 years and compared them to 23 normal lung tissues. Cases with cytoplasmic and nuclear CDK4 immunostaining score values greater than or equal to 7 were regarded as high expression while scores less than 7 were considered low expression. The correlation between the expression level of CDK4 and clinical features was analyzed. Furthermore, we used lentiviral-mediated shRNA to suppress the expression of CDK4 and investigate its function and molecular mechanism for mediating cell cycle progression. RESULTS: The expression level of CDK4 protein was significantly increased in lung cancer tissues compared to normal tissues (P < 0.001). In addition, high levels of CDK4 protein were positively correlated with the status of pathology classification (P = 0.047), lymph node metastasis (P = 0.007), and clinical stage (P = 0.004) of lung cancer patients. Patients with higher CDK4 expression had a markedly shorter overall survival time than patients with low CDK4 expression. Multivariate analysis suggested the level of CDK4 expression was an independent prognostic indicator (P < 0.001) for the survival of patients with lung cancer. Use of lentiviral-mediated shRNA to inhibit the expression of CDK4 in lung cancer cell line A549 not only inhibited cell cycle progression, but also dramatically suppressed cell proliferation, colony formation, and migration. Furthermore, suppressing CDK4 expression also significantly elevated the expression of cell cycle regulator p21 CONCLUSION: Overexpressed CDK4 is a potential unfavorable prognostic factor and mediates cell cycle progression by regulating the expression of p21 in lung cancer |
format | Text |
id | pubmed-3094221 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-30942212011-05-14 Elevated expression of CDK4 in lung cancer Wu, Aibing Wu, Bin Guo, Jinsong Luo, Weiren Wu, Dong Yang, Huiling Zhen, Yan Yu, Xiaoli Wang, Hao Zhou, Ying Liu, Zhen Fang, Weiyi Yang, Zhixiong J Transl Med Research BACKGROUND: The aim of the present study was to analyze the expression of Cyclin-dependent kinase 4 (CDK4) in lung cancer and its correlation with clinicopathologic features. Furthermore, the involvement of CDK4-mediated cell cycle progression and its molecular basis were investigated in the pathogenesis of lung cancer. METHODS: Using immunohistochemistry analysis, we analyzed CDK4 protein expression in 89 clinicopathologically characterized lung cancer patients (59 males and 30 females) with ages ranging from 36 to 78 years and compared them to 23 normal lung tissues. Cases with cytoplasmic and nuclear CDK4 immunostaining score values greater than or equal to 7 were regarded as high expression while scores less than 7 were considered low expression. The correlation between the expression level of CDK4 and clinical features was analyzed. Furthermore, we used lentiviral-mediated shRNA to suppress the expression of CDK4 and investigate its function and molecular mechanism for mediating cell cycle progression. RESULTS: The expression level of CDK4 protein was significantly increased in lung cancer tissues compared to normal tissues (P < 0.001). In addition, high levels of CDK4 protein were positively correlated with the status of pathology classification (P = 0.047), lymph node metastasis (P = 0.007), and clinical stage (P = 0.004) of lung cancer patients. Patients with higher CDK4 expression had a markedly shorter overall survival time than patients with low CDK4 expression. Multivariate analysis suggested the level of CDK4 expression was an independent prognostic indicator (P < 0.001) for the survival of patients with lung cancer. Use of lentiviral-mediated shRNA to inhibit the expression of CDK4 in lung cancer cell line A549 not only inhibited cell cycle progression, but also dramatically suppressed cell proliferation, colony formation, and migration. Furthermore, suppressing CDK4 expression also significantly elevated the expression of cell cycle regulator p21 CONCLUSION: Overexpressed CDK4 is a potential unfavorable prognostic factor and mediates cell cycle progression by regulating the expression of p21 in lung cancer BioMed Central 2011-04-11 /pmc/articles/PMC3094221/ /pubmed/21477379 http://dx.doi.org/10.1186/1479-5876-9-38 Text en Copyright ©2011 Wu et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Wu, Aibing Wu, Bin Guo, Jinsong Luo, Weiren Wu, Dong Yang, Huiling Zhen, Yan Yu, Xiaoli Wang, Hao Zhou, Ying Liu, Zhen Fang, Weiyi Yang, Zhixiong Elevated expression of CDK4 in lung cancer |
title | Elevated expression of CDK4 in lung cancer |
title_full | Elevated expression of CDK4 in lung cancer |
title_fullStr | Elevated expression of CDK4 in lung cancer |
title_full_unstemmed | Elevated expression of CDK4 in lung cancer |
title_short | Elevated expression of CDK4 in lung cancer |
title_sort | elevated expression of cdk4 in lung cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3094221/ https://www.ncbi.nlm.nih.gov/pubmed/21477379 http://dx.doi.org/10.1186/1479-5876-9-38 |
work_keys_str_mv | AT wuaibing elevatedexpressionofcdk4inlungcancer AT wubin elevatedexpressionofcdk4inlungcancer AT guojinsong elevatedexpressionofcdk4inlungcancer AT luoweiren elevatedexpressionofcdk4inlungcancer AT wudong elevatedexpressionofcdk4inlungcancer AT yanghuiling elevatedexpressionofcdk4inlungcancer AT zhenyan elevatedexpressionofcdk4inlungcancer AT yuxiaoli elevatedexpressionofcdk4inlungcancer AT wanghao elevatedexpressionofcdk4inlungcancer AT zhouying elevatedexpressionofcdk4inlungcancer AT liuzhen elevatedexpressionofcdk4inlungcancer AT fangweiyi elevatedexpressionofcdk4inlungcancer AT yangzhixiong elevatedexpressionofcdk4inlungcancer |